C5AR1 and amyloidosis: Our results clearly show that following the intermittent treatment of a transgenic mouse model of AD with a modified C5aR agonist not only reduces fibrillar and pre-fibrillar amyloid load in the brain but also enhances spatial memory in a meaningful capacity, thus exerting a significant improvement in the animals’ AD-related pathology.